Mehtap Aydin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mehtap Aydin has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- Lütfiye Nilsun Altunal
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Türkiye
13 shared publications - Önder Ergönül
Department of Infectious Diseases and Clinical Microbiology, Koç University School of Medicine, Istanbul, Türkiye
9 shared publications - Ayse Serra Ozel
UNIVERSITY OF HEALTH SCIENCES, İSTANBUL ÜMRANİYE HEALTH RESEARCH CENTER, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF CHILD HEALTH AND DISEASES, INFECTIOUS DISEASES
6 shared publications - Şiran Keske
Department of Infectious Diseases and Clinical Microbiology, Koç University School of Medicine, Istanbul, Türkiye
5 shared publications - Alpay Azap
Department of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, Turkey
4 shared publications - Ayse Batirel
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Istanbul Kartal Dr. Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye
4 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- p. 330
Infection Prevention and Control in Türkiye: A Consensus Report from the 7th National Healthcare-Associated Infections Symposium
Antimicrobial resistance continues to threaten modern healthcare systems, increasing the importance of effective infection prevention and control (IPC). This study presents a thematic analysis of discussions from the 7th National Healthcare-Associated Infections Symposium (Ulusal Sağlık Bakımıyla İlişkili İnfeksiyonlar Simpozyumu, USBİS). Audio-recorded sessions involving IPC leaders and healthcare professionals across Türkiye were transcribed and analyzed to identify persistent barriers and potential solutions. Key barriers included reporting pressures affecting data reliability, behavioral and cultural barriers, limitations in education and workforce capacity, gaps in standardization, and difficulties implementing infection control committee decisions. Participants emphasized strengthening institutional IPC culture, improving leadership visibility, simplifying data systems, and prioritizing sustainable behavioral change strategies.
- 28 July 2026
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- p. 330
Open AccessInfection Prevention and Control in Türkiye: A Consensus Report from the 7th National Healthcare-Associated Infections Symposium
Antimicrobial resistance continues to threaten modern healthcare systems, increasing the importance of effective infection prevention and control (IPC). This study presents a thematic analysis of discussions from the 7th National Healthcare-Associated Infections Symposium (Ulusal Sağlık Bakımıyla İlişkili İnfeksiyonlar Simpozyumu, USBİS). Audio-recorded sessions involving IPC leaders and healthcare professionals across Türkiye were transcribed and analyzed to identify persistent barriers and potential solutions. Key barriers included reporting pressures affecting data reliability, behavioral and cultural barriers, limitations in education and workforce capacity, gaps in standardization, and difficulties implementing infection control committee decisions. Participants emphasized strengthening institutional IPC culture, improving leadership visibility, simplifying data systems, and prioritizing sustainable behavioral change strategies.
- 14 February 2026
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
Correction to: The Turkish Clinical Microbiology and Infectious Diseases Society (KLİMİK) Evidence-Based Guideline for the Diagnosis and Treatment of Brucellosis, 2023
CORRECTION NOTE Two corrections have been made to the original version of this article, published on February 2, 2023: In Table 3, the information ‘DOX tablet 200 mg/day, single dose, oral +’ under the headings 1)Infective Endocarditis associated with Brucella spp. and 2) Neurobrucellosis has been corrected to: ‘DOX tablet 200 mg/day, 2 doses, oral +’. Corrected article: https://doi.org/10.36519/kd.2023.4576
- 14 February 2026
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
Correction to: The Turkish Clinical Microbiology and Infectious Diseases Society (KLİMİK) Evidence-Based Guideline for the Diagnosis and Treatment of Brucellosis, 2023
CORRECTION NOTE Two corrections have been made to the original version of this article, published on February 2, 2023: In Table 3, the information ‘DOX tablet 200 mg/day, single dose, oral +’ under the headings 1)Infective Endocarditis associated with Brucella spp. and 2) Neurobrucellosis has been corrected to: ‘DOX tablet 200 mg/day, 2 doses, oral +’. Corrected article: https://doi.org/10.36519/kd.2023.4576
- Open Access
- 29 December 2025
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- p. 221
Bone-Mineral Density in HIV-Positive Individuals Under 50 Years of Age: A Case-Control Study
Objective: HIV infection may negatively impact bone microarchitecture, leading to reduced bone mineral density (BMD). This study compared the BMD of individuals under the age of 50 living with HIV to that of HIV-negative controls and evaluated the effect of antiretroviral therapy (ART) on BMD. Methods: In this cross-sectional case-control study conducted at the University of Health Sciences Ümraniye Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, medical records of 72 HIV-positive and 44 HIV-negative individuals aged 18–49 years were retrospectively reviewed between December 2021 and March 2022. Bone mineral density was measured using dual-energy X-ray absorptiometry (DEXA). Results: The prevalence of low BMD was 16.7% among HIV-positive individuals and 6.8% among HIV-negative controls. Lumbar spine T- and Z-scores were significantly lower in the HIV-positive group (ppp<0.05). No significant association was observed between BMD and CD4+ T cell count, viral load, vitamin D, or calcium levels. Conclusion: Individuals under 50 years of age living with HIV have lower BMD compared to HIV-negative individuals. These findings suggest that HIV infection may contribute to decreased BMD even in younger populations. Dual-energy X-ray absorptiometry screening should be considered in HIV-positive individuals under 50 years of age with additional risk factors for reduced BMD. Larger, multicenter studies are needed to confirm these results.
- 29 December 2025
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- p. 221
Open AccessBone-Mineral Density in HIV-Positive Individuals Under 50 Years of Age: A Case-Control Study
Objective: HIV infection may negatively impact bone microarchitecture, leading to reduced bone mineral density (BMD). This study compared the BMD of individuals under the age of 50 living with HIV to that of HIV-negative controls and evaluated the effect of antiretroviral therapy (ART) on BMD. Methods: In this cross-sectional case-control study conducted at the University of Health Sciences Ümraniye Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, medical records of 72 HIV-positive and 44 HIV-negative individuals aged 18–49 years were retrospectively reviewed between December 2021 and March 2022. Bone mineral density was measured using dual-energy X-ray absorptiometry (DEXA). Results: The prevalence of low BMD was 16.7% among HIV-positive individuals and 6.8% among HIV-negative controls. Lumbar spine T- and Z-scores were significantly lower in the HIV-positive group (ppp<0.05). No significant association was observed between BMD and CD4+ T cell count, viral load, vitamin D, or calcium levels. Conclusion: Individuals under 50 years of age living with HIV have lower BMD compared to HIV-negative individuals. These findings suggest that HIV infection may contribute to decreased BMD even in younger populations. Dual-energy X-ray absorptiometry screening should be considered in HIV-positive individuals under 50 years of age with additional risk factors for reduced BMD. Larger, multicenter studies are needed to confirm these results.
- Open Access
- 25 September 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (3) , 273-282
Impact of the COVID-19 Pandemic on CLABSI Rates and Antibiotic Resistance: A Multicenter Study in Türkiye
Healthcare-associated infections (HAIs) are common yet largely preventable through adherence to evidence-based guidelines. In 2005, Türkiye implemented a national infection control program, which led to significant reductions in HAI rates, including a 50% decrease in central line-associated bloodstream infections (CLABSIs) between 2008 and 2017. This result was in parallel with data from
- 25 September 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (3) , 273-282
Open AccessImpact of the COVID-19 Pandemic on CLABSI Rates and Antibiotic Resistance: A Multicenter Study in Türkiye
Healthcare-associated infections (HAIs) are common yet largely preventable through adherence to evidence-based guidelines. In 2005, Türkiye implemented a national infection control program, which led to significant reductions in HAI rates, including a 50% decrease in central line-associated bloodstream infections (CLABSIs) between 2008 and 2017. This result was in parallel with data from
- Open Access
- 28 April 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (7) , 1659-1666
Emerging West Nile virus infections in Türkiye
Purpose: Türkiye experienced its largest West Nile virus (WNV) infection outbreak in 2024. We described the clinical and laboratory features of human cases with WNV infection collected from eleven tertiary hospitals in Türkiye in 2024. Methods: The clinical characteristics of the patients were gathered using a structured form in the retrospective study. According to the ECDC case definition of WNV infections, the patients were classified as ‘confirmed’ or ‘probable’ cases. The odds ratio (OR) and 95% confidence interval (CI) for possible mortality predictors in WNV infections were calculated using multivariate logistic regression analysis. p < 0.05 was considered statistically significant. Results: The mean age of the 51 patients was 63.3 ± 13.6 years, and 37 (72.5%) were male. Twenty-six cases (51%) were confirmed, and 49% were probable WNV infection. Forty-eight patients (94.1%) had WNV neuroinvasive disease: 24 (47%) were diagnosed with meningoencephalitis, 20 (39.2%) with encephalitis, one (2%) with meningitis, and seven (13.7%) with acute flaccid paralysis. Twenty patients (39.2%) had movement disorders (tremor, myoclonus, bradykinesia, or rigidity). The case fatality rate was 17.6%. In multivariate analysis, older age (OR: 1.09, CI: 1.03–1.19, p = 0.042) and secondary bacterial infection during hospitalization (OR: 10, CI: 1.55–64.95, p = 0.015) were associated with fatality. Conclusion: We highlighted the increasing number of cases and diagnostic challenges by describing the highest number of the patients with WNV infections in Türkiye. Raising awareness among healthcare professionals, facilitating access to diagnostic tests, and developing rapid, reliable, and easily applicable tests would enable early diagnosis and help improve outcomes.
- 28 April 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (7) , 1659-1666
Open AccessEmerging West Nile virus infections in Türkiye
Purpose: Türkiye experienced its largest West Nile virus (WNV) infection outbreak in 2024. We described the clinical and laboratory features of human cases with WNV infection collected from eleven tertiary hospitals in Türkiye in 2024. Methods: The clinical characteristics of the patients were gathered using a structured form in the retrospective study. According to the ECDC case definition of WNV infections, the patients were classified as ‘confirmed’ or ‘probable’ cases. The odds ratio (OR) and 95% confidence interval (CI) for possible mortality predictors in WNV infections were calculated using multivariate logistic regression analysis. p < 0.05 was considered statistically significant. Results: The mean age of the 51 patients was 63.3 ± 13.6 years, and 37 (72.5%) were male. Twenty-six cases (51%) were confirmed, and 49% were probable WNV infection. Forty-eight patients (94.1%) had WNV neuroinvasive disease: 24 (47%) were diagnosed with meningoencephalitis, 20 (39.2%) with encephalitis, one (2%) with meningitis, and seven (13.7%) with acute flaccid paralysis. Twenty patients (39.2%) had movement disorders (tremor, myoclonus, bradykinesia, or rigidity). The case fatality rate was 17.6%. In multivariate analysis, older age (OR: 1.09, CI: 1.03–1.19, p = 0.042) and secondary bacterial infection during hospitalization (OR: 10, CI: 1.55–64.95, p = 0.015) were associated with fatality. Conclusion: We highlighted the increasing number of cases and diagnostic challenges by describing the highest number of the patients with WNV infections in Türkiye. Raising awareness among healthcare professionals, facilitating access to diagnostic tests, and developing rapid, reliable, and easily applicable tests would enable early diagnosis and help improve outcomes.
- Open Access
- 27 March 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (1) , 17-26
Healthcare-Associated Infection Rates in Türkiye (2014-2023): A Systematic Review and Meta-Analysis
Healthcare-associated infections (HAIs) are accepted as one of the most important challenges in hospital settings. They cause extended lengths of stay -at the hospital, threatening patient safety, increasing the rate of morbidity and mortality, raising the workforce of healthcare workers and accelerating antimicrobial resistance. According to the World Health Organization (WHO),
- 27 March 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (1) , 17-26
Open AccessHealthcare-Associated Infection Rates in Türkiye (2014-2023): A Systematic Review and Meta-Analysis
Healthcare-associated infections (HAIs) are accepted as one of the most important challenges in hospital settings. They cause extended lengths of stay -at the hospital, threatening patient safety, increasing the rate of morbidity and mortality, raising the workforce of healthcare workers and accelerating antimicrobial resistance. According to the World Health Organization (WHO),
- Open Access
- 27 March 2025
- Vol. 7 (1) , 17-26
Healthcare-Associated Infection Rates in Türkiye (2014-2023): A Systematic Review and Meta-Analysis
This study aimed to describe the rate of Healthcare-Associated Infections (HAIs) in hospitals in the last decade (2014-2023), Türkiye. The study was conducted using the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statements. The keywords were “Türkiye”, “healthcare-associated infections” (HAIs), “surgical site infections” (SSIs), “central line-catheter-associated bloodstream infections” (CLABSIs), “catheter-associated urinary tract infections” (CAUTI) and “ventilator-associated pneumonia” (VAP). We included all original articles reflecting the HAI rate of all adult patients in hospitals in Türkiye for at least one year of duration between January 01, 2014 and December 31, 2023. In total, 1171 reports, including the keywords, were retrieved, and duplications were removed. After filtering according to the title and abstract, eight original articles were selected. The quality of four reports published in peer-reviewed journals was rated as high, and the four as moderate. The rate of invasive device-associated HAIs in intensive care units (ICUs) was 4.19 (CLABSI: 1.97, CAUTI: 1.94, VAP: 6.49) and 1.88 in inpatient wards. No article was published that reflected the overall surgical site infection rate of a hospital. We detected that in the last 10 years (2014-2023) in Türkiye, invasive device-associated HAI rates were 1.88% in inpatient wards and 4.19% in ICU. More comprehensive studies should be conducted on HAI rates, frequently detected HAI agents, and resistance rates. Health centers should prioritize the issue, and intervention and prevention studies should be priority research topics.
- 27 March 2025
- Vol. 7 (1) , 17-26
Open AccessHealthcare-Associated Infection Rates in Türkiye (2014-2023): A Systematic Review and Meta-Analysis
This study aimed to describe the rate of Healthcare-Associated Infections (HAIs) in hospitals in the last decade (2014-2023), Türkiye. The study was conducted using the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statements. The keywords were “Türkiye”, “healthcare-associated infections” (HAIs), “surgical site infections” (SSIs), “central line-catheter-associated bloodstream infections” (CLABSIs), “catheter-associated urinary tract infections” (CAUTI) and “ventilator-associated pneumonia” (VAP). We included all original articles reflecting the HAI rate of all adult patients in hospitals in Türkiye for at least one year of duration between January 01, 2014 and December 31, 2023. In total, 1171 reports, including the keywords, were retrieved, and duplications were removed. After filtering according to the title and abstract, eight original articles were selected. The quality of four reports published in peer-reviewed journals was rated as high, and the four as moderate. The rate of invasive device-associated HAIs in intensive care units (ICUs) was 4.19 (CLABSI: 1.97, CAUTI: 1.94, VAP: 6.49) and 1.88 in inpatient wards. No article was published that reflected the overall surgical site infection rate of a hospital. We detected that in the last 10 years (2014-2023) in Türkiye, invasive device-associated HAI rates were 1.88% in inpatient wards and 4.19% in ICU. More comprehensive studies should be conducted on HAI rates, frequently detected HAI agents, and resistance rates. Health centers should prioritize the issue, and intervention and prevention studies should be priority research topics.
- Open Access
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (3) , 111-117
A Systematic Review and Analysis of Brucella Endocarditis Cases
Endocarditis is the most common cause of death from brucellosis. The information used to guide the management of cases with Brucella endocarditis has relied on case reports/series. Risk factors related to death and other adverse outcomes in patients with Brucella endocarditis were identified by an individual-patient data analysis of all reported Brucella endocarditis cases in the literature. The keywords “Bruce” and “endocard” were used to search articles published until July 2022 on PubMed and ULAKBIM databases. Case reports/series containing patients with endocarditis caused by Brucella spp., aged ≥17 years, and with data on antimicrobial or surgical treatment were included in the study. Epidemiological, clinical, laboratory, and treatment characteristics and outcomes of 273 cases from 86 eligible articles were recorded. It was found that male gender, a Wright serum tube agglutination (STA) titer of ≥1/1280 on admission, development of heart failure due to endocarditis were independent risk factors that increase mortality, while the usage of aminoglycoside and cardiac surgical intervention for endocarditis were factors reducing mortality. Including streptomycin or gentamicin in the treatment regimen may benefit patients with Brucella endocarditis. Valve surgery could be life-saving in patients with Brucella endocarditis. An STA titer of ≥1/1280, which probably reflects long-term and advanced disease, may be used as a marker for increased mortality. However, additional and more reliable studies are needed to define the most appropriate management approach in diagnosing and treating cases with Brucella endocarditis due to the low quality of the current evidence.
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (3) , 111-117
Open AccessA Systematic Review and Analysis of Brucella Endocarditis Cases
Endocarditis is the most common cause of death from brucellosis. The information used to guide the management of cases with Brucella endocarditis has relied on case reports/series. Risk factors related to death and other adverse outcomes in patients with Brucella endocarditis were identified by an individual-patient data analysis of all reported Brucella endocarditis cases in the literature. The keywords “Bruce” and “endocard” were used to search articles published until July 2022 on PubMed and ULAKBIM databases. Case reports/series containing patients with endocarditis caused by Brucella spp., aged ≥17 years, and with data on antimicrobial or surgical treatment were included in the study. Epidemiological, clinical, laboratory, and treatment characteristics and outcomes of 273 cases from 86 eligible articles were recorded. It was found that male gender, a Wright serum tube agglutination (STA) titer of ≥1/1280 on admission, development of heart failure due to endocarditis were independent risk factors that increase mortality, while the usage of aminoglycoside and cardiac surgical intervention for endocarditis were factors reducing mortality. Including streptomycin or gentamicin in the treatment regimen may benefit patients with Brucella endocarditis. Valve surgery could be life-saving in patients with Brucella endocarditis. An STA titer of ≥1/1280, which probably reflects long-term and advanced disease, may be used as a marker for increased mortality. However, additional and more reliable studies are needed to define the most appropriate management approach in diagnosing and treating cases with Brucella endocarditis due to the low quality of the current evidence.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (1) , e20230671
Use of high-dose steroid therapy: addition of anakinra in the treatment of severe COVID-19
The aim of this study was to compare the clinical effects of the addition of anakinra to high-dose steroid therapy in COVID-19 patients with macrophage activation syndrome.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (1) , e20230671
Open AccessUse of high-dose steroid therapy: addition of anakinra in the treatment of severe COVID-19
The aim of this study was to compare the clinical effects of the addition of anakinra to high-dose steroid therapy in COVID-19 patients with macrophage activation syndrome.
- Open Access
Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study
The immunogenicity of vaccines decreases over time, causing a need for booster doses. This study aimed to present the long-term (Day 84) immunogenicity results of the double-blind, randomized, controlled, phase II Hybrid COV-RAPEL TR Study (NCT04979949), in which the TURKOVAC or CoronaVac vaccines were used as a booster after the second dose of primary vaccination with CoronaVac. A total of 190 participants from the Hybrid COV-RAPEL TR Study, who had both Day 28 and Day 84 immunogenicity results, were included. The immunogenicity on Day 84, regarding the neutralizing antibody positivity (Wuhan and Delta variants) and anti-spike immunoglobulin (Ig) G (IgG) antibody positivity, was compared between TURKOVAC and CoronaVac vaccine arms according to sex and age groups. Overall, antibody positivity showed a slight decrease on Day 84 vs. Day 28, but was not different between TURKOVAC and CoronaVac arms either for sexes or for age groups. However, TURKOVAC produced better antibody response against the Delta variant than CoronaVac, while CoronaVac was superior over TURKOVAC regarding neutralizing antibody positivity in the 50–60 years age group, regardless of the variant. A single booster dose, after the completion of the primary vaccination, increases antibody positivity on Day 28 which persists until Day 84 with a slight decrease. However, an additional booster dose may be required thereafter, since the decrease in antibody titer may be faster over time.
Open AccessLong-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study
The immunogenicity of vaccines decreases over time, causing a need for booster doses. This study aimed to present the long-term (Day 84) immunogenicity results of the double-blind, randomized, controlled, phase II Hybrid COV-RAPEL TR Study (NCT04979949), in which the TURKOVAC or CoronaVac vaccines were used as a booster after the second dose of primary vaccination with CoronaVac. A total of 190 participants from the Hybrid COV-RAPEL TR Study, who had both Day 28 and Day 84 immunogenicity results, were included. The immunogenicity on Day 84, regarding the neutralizing antibody positivity (Wuhan and Delta variants) and anti-spike immunoglobulin (Ig) G (IgG) antibody positivity, was compared between TURKOVAC and CoronaVac vaccine arms according to sex and age groups. Overall, antibody positivity showed a slight decrease on Day 84 vs. Day 28, but was not different between TURKOVAC and CoronaVac arms either for sexes or for age groups. However, TURKOVAC produced better antibody response against the Delta variant than CoronaVac, while CoronaVac was superior over TURKOVAC regarding neutralizing antibody positivity in the 50–60 years age group, regardless of the variant. A single booster dose, after the completion of the primary vaccination, increases antibody positivity on Day 28 which persists until Day 84 with a slight decrease. However, an additional booster dose may be required thereafter, since the decrease in antibody titer may be faster over time.